Company Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-31 pm EDT			5-day change	1st Jan Change
3.19 ^USD	-3.92%		-3.33%	-35.56%

May. 06	Genenta Science S.p.A. Announces New Board Appointments	CI
Apr. 08	Genenta Science S.P.A. Announces Resignation of Board Members	CI

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

Number of employees: 14

Managers	Title	Age	Since
Bernhard Gentner FOU	Founder	-	14-07-23
Luigi Naldini FOU	Founder	-	14-07-23
Pierluigi Paracchi CEO	Chief Executive Officer	50	14-07-23
Richard B. Slansky DFI	Director of Finance/CFO	67	21-05-19
Carlo Russo CTO	Chief Tech/Sci/R&D Officer	71	20-12-31
Timothy J. Obara PRN	Corporate Officer/Principal	-	22-10-23

Members of the board	Title	Age	Since
Anthony Marucci BRD	Director/Board Member	62	21-05-19
Roger Abravanel BRD	Director/Board Member	77	21-05-19
Pierluigi Paracchi CEO	Chief Executive Officer	50	14-07-23
Guido Guidi BRD	Director/Board Member	71	16-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,216,858	18,034,689 ( 99.00 %)	0	80.08 %
Stock B	1	18,216,958	11,141,840 ( 61.16 %)	0

Name	Equities	%	Valuation
Bank Julius Bär & Co. AG 2.115 %	385,313	2.115 %	1 M $
Kairos Partners SGR SpA 1.926 %	350,839	1.926 %	1 M $
Investitori SGR SpA 0.5116 %	93,200	0.5116 %	271 585 $
Anthilia Capital Partners SGR SpA 0.4367 %	79,554	0.4367 %	231 820 $
Algebris (UK) Ltd. 0.2470 %	45,000	0.2470 %	131 130 $
Lemanik Invest SA 0.0946 %	17,226	0.0946 %	50 197 $
BG Fund Management Luxembourg SA 0.0143 %	2,600	0.0143 %	7 576 $
Morgan Stanley Smith Barney LLC 0.002745 %	500	0.002745 %	1 457 $
UBS Securities LLC 0.000225 %	41	0.000225 %	119 $

Name	Equities	%	Valuation
Pierluigi Paracchi 12.60 %	2,294,421	12.60 %	7 M $
Raffaele Ospedale San 10.41 %	1,896,730	10.41 %	6 M $
Luigi Naldini 7.609 %	1,386,145	7.609 %	4 M $
Bernhard Gentner 3.803 %	692,871	3.803 %	2 M $
Carlo Russo 3.285 %	598,417	3.285 %	2 M $
Roger Abravanel 0.4346 %	79,165	0.4346 %	230 687 $
Richard B. Slansky 0.3949 %	71,940	0.3949 %	209 633 $
Guido Guidi 0.3543 %	64,539	0.3543 %	188 067 $
Stefania Mazzoleni 0.2285 %	41,620	0.2285 %	121 281 $
Mark Sirgo 0.1912 %	34,822	0.1912 %	101 471 $

Genenta Science SpA

Via Olgettina No. 58

20132, Milan

http://www.genenta.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.941 EUR

Average target price

21.36 EUR

Spread / Average Target

+626.19%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENENTA SCIENCE S.P.A.	-35.56%	58.34M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research